These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 24858256)

  • 1. Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2.
    Goyal S; Grover S; Dhanjal JK; Tyagi C; Goyal M; Grover A
    J Mol Graph Model; 2014 Jun; 51():64-72. PubMed ID: 24858256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
    Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
    J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular dynamics simulations studies and free energy analysis on inhibitors of MDM2-p53 interaction.
    Niu RJ; Zheng QC; Zhang JL; Zhang HX
    J Mol Graph Model; 2013 Nov; 46():132-9. PubMed ID: 24211465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.
    Patil SP; Pacitti MF; Gilroy KS; Ruggiero JC; Griffin JD; Butera JJ; Notarfrancesco JM; Tran S; Stoddart JW
    J Comput Aided Mol Des; 2015 Feb; 29(2):155-63. PubMed ID: 25377899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
    Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y
    Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
    Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
    Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into mechanism of small molecule inhibitors of the MDM2-p53 interaction: molecular dynamics simulation and free energy analysis.
    Chen J; Wang J; Xu B; Zhu W; Li G
    J Mol Graph Model; 2011 Sep; 30():46-53. PubMed ID: 21764342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GQSAR modeling and combinatorial library generation of 4-phenylquinazoline-2-carboxamide derivatives as antiproliferative agents in human Glioblastoma tumors.
    Goswami D; Goyal S; Jamal S; Jain R; Wahi D; Grover A
    Comput Biol Chem; 2017 Aug; 69():147-152. PubMed ID: 28420545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposing novel MDM2 inhibitors: Combined physics-driven high-throughput virtual screening and in vitro studies.
    Aydin G; Paksoy MN; Orhan MD; Avsar T; Yurtsever M; Durdagi S
    Chem Biol Drug Des; 2020 Jul; 96(1):684-700. PubMed ID: 32691963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QSAR models for isoindolinone-based p53-MDM2 interaction inhibitors using linear and non-linear statistical methods.
    Dong X; Yan J; Lu D; Wu P; Gao J; Liu T; Yang B; Hu Y
    Chem Biol Drug Des; 2012 May; 79(5):691-702. PubMed ID: 22233482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment based G-QSAR and molecular dynamics based mechanistic simulations into hydroxamic-based HDAC inhibitors against spinocerebellar ataxia.
    Sinha S; Tyagi C; Goyal S; Jamal S; Somvanshi P; Grover A
    J Biomol Struct Dyn; 2016 Oct; 34(10):2281-95. PubMed ID: 26510381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
    Wang W; Shangguan S; Qiu N; Hu C; Zhang L; Hu Y
    Bioorg Med Chem; 2013 Jun; 21(11):2879-85. PubMed ID: 23601819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.
    Wang Y; Zhu J; Liu JJ; Chen X; Mihalic J; Deignan J; Yu M; Sun D; Kayser F; McGee LR; Lo MC; Chen A; Zhou J; Ye Q; Huang X; Long AM; Yakowec P; Oliner JD; Olson SH; Medina JC
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3782-5. PubMed ID: 25042256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease.
    Gurung AB; Aguan K; Mitra S; Bhattacharjee A
    J Biomol Struct Dyn; 2017 Jun; 35(8):1729-1742. PubMed ID: 27410776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing the Free-Energy Landscape of MDM2 Protein-Ligand Interactions by Steered Molecular Dynamics Simulations.
    Hu G; Xu S; Wang J
    Chem Biol Drug Des; 2015 Dec; 86(6):1351-9. PubMed ID: 26032728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.
    Gureev M; Novikova D; Grigoreva T; Vorona S; Garabadzhiu A; Tribulovich V
    J Comput Aided Mol Des; 2020 Jan; 34(1):55-70. PubMed ID: 31781989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
    Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
    Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
    Liao G; Yang D; Ma L; Li W; Hu L; Zeng L; Wu P; Duan L; Liu Z
    Eur J Med Chem; 2018 Nov; 159():1-9. PubMed ID: 30253242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.